The growing global burden of colorectal cancer (CRC), particularly in low- and middle-income countries (LMICs) like Nigeria, has underscored the urgent need for innovative approaches to early ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

The combination of autogene cevumeran with PD-1 blockade was well-tolerated with adverse events consistent with the known safety profiles of the individual treatments. We are continuing to analyze ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

Evercore ISI initiated coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat.com reports. The firm issued an ...

European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...